Causal treatment of ZDI consists of therapy of the underlying condition, if this is possible.
Symptomatic therapy can be given with desmopressin, a vasopressin analogue, which is available for i. v., s. c. intranasal or oral use (Herold 2021). The normal dose is
- approx. 2 - 3 x 100 - 400 µg / d orally
- approx. 2 - 3 x 10 - 20 µg / d as a nasal spray
(Kasper 2015)
The amount of the dose depends on the urine volume and serum sodium values (Fassnacht 2019).
An uncomplicated ZDI can be completely eliminated with this (Kasper 2015).
If some ADH is still present, additional medications that include
- enhance the release of ADH are used such as:
- Drugs that complement the action of ADH such as:
- Chlorpropamide
- Carbamazepine
(Kuhlmann 2015)
- Gestational diabetes insipidus:
Gestational diabetes insipidus does not respond to ADH. Treatment in this case is with desmopressin (Lehnert 2010).
Dosage recommendation: 0.05 - 0.02 ml (5 - 20 µg) of solution (100 µg / ml) intranasally (Paumgartner 2013). The exact dosage depends on the urine volume and serum sodium (Fassnacht 2019).
Neurosurgical patients should be educated about the symptoms of possible ZDI preoperatively. It is also recommended to have serum electrolytes determined regularly until the 10th p. o. day (Fassnacht 2019).
The treatment of p.o. diabetes insipidus consists in administrations of desmopressin i. v. or s. c.,
Recommended dosage: 0.25 - 1.0 µg every 12 - 24 hours.
The primary goal of treatment is normalization of urine volume and serum sodium.
If the ZDI persists at discharge, oral or intranasal administration can be switched to.
The patient should be informed about possible side effects of the medication (such as nausea, vomiting, headache and, in the case of progressive hyponatremia, unconsciousness or even coma), as immediate consultation with the treating physician may be necessary due to pausing the medication.
(Fassnacht 2019)